Q4 2025 Solesence Inc Earnings Call Transcript
Key Points
- Solesence Inc (SLSN) achieved record revenue of $62.1 million for the full year 2025, marking an 18.6% increase from 2024.
- The company reported a net income of $163,000 for Q4 2025, a significant improvement from a net loss of $558,000 in the previous year.
- Gross margin improved to 27% in Q4 2025 from 22% in the same period in 2024.
- Solesence Inc (SLSN) increased its patent portfolio by 20%, enhancing its market position and providing leverage for brand partners.
- The company launched the Transform and Transcend initiative, focusing on operational excellence and technology-driven expansion to improve financial performance.
- Despite revenue growth, full-year gross profit remained flat at $16.1 million compared to $16.2 million in 2024.
- Margins were compressed due to elevated labor costs, product design complexities, and inventory control issues.
- The company experienced yield volatility and associated losses, impacting the bottom line.
- Open orders decreased to just under $33 million from $38 million a year ago, indicating a period of revenue normalization.
- First quarter results for 2026 are expected to be impacted by investments in training and restructuring, as well as changes in customer order patterns.
Good day, and thank you for standing by. Welcome to the Solesence fourth quarter and full year 2025 conference call. Today's call is being recorded.
During this call, management will make statements that include forward-looking statements within the meeting of the federal security laws, which are pursuant to the Safe Harbor provisions of the Private Securities Litigation Reform Act of 1995.
This conference call may contain statements that reflect the company's current beliefs and a number of important factors could cause actual results for future periods to differ materially from those stated on this call. These important factors include, without limitation, a discussion of a customer to cancel purchase order or supply agreements, demand for acceptance of the company's personal care ingredients,
Advanced Materials and formulated products. Changes in development and distribution relationships, the impact of the competitive products and technology, possible disruption in commercial activities occasioned by public health issues, terrorist activities and armed conflicts and other
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
